Clusters of differentiation

Shattuck Labs to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 11, 2021

Retrieved on: 
Wednesday, August 4, 2021

The live call may be accessed by dialing (833) 614-1555 (domestic) or (516) 575-8754 (international) and entering the conference code: 7172288.

Key Points: 
  • The live call may be accessed by dialing (833) 614-1555 (domestic) or (516) 575-8754 (international) and entering the conference code: 7172288.
  • The live and archived webcast will be available on the Events& Presentations section of the Companys website.
  • Compounds derived from Shattucks proprietary Agonist Redirected Checkpoint, ARC, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules within a single therapeutic.
  • A second compound, SL-279252 (PD1-Fc-OX40L), is being evaluated in a Phase 1 trial in collaboration with Takeda Pharmaceuticals.

Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, "Off-the-Shelf", Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma

Retrieved on: 
Monday, August 2, 2021

First allogeneic, off-the-shelf anti-CD38 DAR-T cell therapy cleared for Phase 1 clinical trial in Relapsed or Refractory Multiple Myeloma.

Key Points: 
  • First allogeneic, off-the-shelf anti-CD38 DAR-T cell therapy cleared for Phase 1 clinical trial in Relapsed or Refractory Multiple Myeloma.
  • CD38 DAR-T is the first allogeneic, off-the-shelf clinical-stage cellular therapy product candidate based on Sorrentos proprietary Dimeric Antigen Receptor (DAR) T cell platform.
  • SAN DIEGO, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the FDA has authorized Sorrentos IND application for the Phase 1 clinical testing of its allogeneic anti-CD38 Dimeric Antigen Receptor (DAR) - T Cell therapy for relapsed or refractory multiple myeloma.
  • RTX has completed a Phase IB trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients.

Eledon Pharmaceuticals to Release Second Quarter Financial Results on Thursday, August 12, 2021

Retrieved on: 
Monday, August 2, 2021

The companys lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential.

Key Points: 
  • The companys lead compound in development is AT-1501, an anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad therapeutic potential.
  • AT-1501 is a humanized IgG1 antibody engineered to potentially both improve safety and provide pharmacokinetic, pharmacodynamic, and dosing advantages compared to other anti-CD40 approaches.
  • Eledon is headquartered in Irvine, Calif. For more information, please visit the companys website at www.eledon.com .
  • Follow Eledon Pharmaceuticals on social media: @Eledon_Pharma and LinkedIn .

Pharmadrug Announces Positive Research Results of Cepharanthine to Treat Multiple Cancers

Retrieved on: 
Wednesday, July 28, 2021

Toronto, Ontario--(Newsfile Corp. - July 28, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce the completion of their preclinical cancer study which evaluated cepharanthine-2HCl, the active pharmaceutical ingredient in PD-001, the Company's patented oral formulation of cepharanthine. The results from the study validate cepharanthine's potential in treating different types of cancer including esophageal, colorectal, liver and skin. The results also provide confidence in the Company's plan to dedicate resources to advance PD-001 through FDA IND-enabling studies to support Phase 1 and 2 clinical studies. The study was conducted by a respected contract research organization with deep expertise in preclinical oncology model development and drug testing and data corresponding to all studied cancer cell lines have now been reported to the Company.

Key Points: 
  • Based on the de-risked and positive results from the study, the Company has initiated the following activities:
    Broadening intellectual property strategy with planned filing of provisional patents on cepharanthine for specific cancers.
  • Cepharanthine has been shown in preclinical efficacy models to restore cancer cell sensitivity to multiple unrelated classes of chemotherapy.
  • In clinical research, Cepharanthine has been shown to exhibit multiple pharmacological properties including anti-oxidative, anti-inflammatory, immuno-regulatory, anti-cancer, anti-viral and anti-parasitic properties5.
  • The Company is focused on advancing the clinical development of an improved oral formulation of Cepharanthine (PD-001) to treat rare cancers and infectious diseases.

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3

Retrieved on: 
Wednesday, July 28, 2021

We have an opportunity to selectively deliver alpha particles to these tumors and use precision radiation therapy as a new treatment paradigm.

Key Points: 
  • We have an opportunity to selectively deliver alpha particles to these tumors and use precision radiation therapy as a new treatment paradigm.
  • While the currently approved pan-FGFR inhibitor for bladder cancer requires the presence of a specific mutation, our approach requires only over-expression of FGFR3.
  • The information that Fusion posts on this website could be deemed to be material information.
  • As a result, Fusion encourages investors, media and others interested to review the information that Fusion posts there on a regular basis.

Bridge Medicines Enters Exclusive License Agreement with Cornell University for UBR5 Inhibitor Program to Treat Resistant Cancers

Retrieved on: 
Wednesday, July 28, 2021

Consequently, attacking the UBR5 target may work well in combination with other immune regulators, such as those that target the PD-L1 pathway.

Key Points: 
  • Consequently, attacking the UBR5 target may work well in combination with other immune regulators, such as those that target the PD-L1 pathway.
  • Collectively, these data support targeting UBR5 as a novel immunotherapy to treat highly aggressive breast cancers that resist conventional therapies.
  • "We are very excited to bring the UBR5 program into Bridge Medicines," said Bill Polvino, CEO of Bridge Medicines.
  • Bridge Medicines is a pioneering drug-discovery company focused on advancing promising early technologies in major academic institutions from proof-of-concept to clinical development.

F-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid Tumors

Retrieved on: 
Monday, July 26, 2021

The ongoing multicenter clinical trial ( NCT04096638 ) is evaluating the safety and efficacy of intravenously (IV) administered SB 11285 alone and in combination with the anti-PD-L1 monoclonal antibody, atezolizumab, in patients with advanced solid tumors.

Key Points: 
  • The ongoing multicenter clinical trial ( NCT04096638 ) is evaluating the safety and efficacy of intravenously (IV) administered SB 11285 alone and in combination with the anti-PD-L1 monoclonal antibody, atezolizumab, in patients with advanced solid tumors.
  • In clinical trials, the first generation of these compounds were typically injected intratumorally in patients with solid cancers.
  • F-stars SB 11285 is differentiated from the first generation of STING agonists, as it is delivered systemically, enabling access to hard-to-reach tumors.
  • Additionally, SB 11285 may facilitate migration of newly activated immune cells from the periphery into the tumor site.

Lee’s Pharmaceutical Announces First Patient Dosed With its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, as a First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

Retrieved on: 
Friday, July 23, 2021

Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lees Pharm.

Key Points: 
  • Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lees Pharm.
  • Socazolimab is a fully human anti-PD-L1 monoclonal antibody identified by Sorrento using its proprietary G-MAB library platform.
  • COF received exclusive rights to develop and commercialize the antibody for Greater China, which includes Mainland China, Hong Kong, Macau, and Taiwan.
  • Forward-looking statements include statements regarding the potential efficacy and safety profile of a Socazolimab product candidate in patients with extensive-stage small-cell lung cancer.

Akoya Announces Publication of the MITRE Study, the First Multi-Institutional Analytical Demonstration of a Spatial Biology Workflow, in the Journal for ImmunoTherapy of Cancer

Retrieved on: 
Monday, July 19, 2021

The paper titled, Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE Study) , was published in the Journal for ImmunoTherapy of Cancer (JITC) in July 2021.

Key Points: 
  • The paper titled, Multi-institutional TSA-amplified Multiplexed Immunofluorescence Reproducibility Evaluation (MITRE Study) , was published in the Journal for ImmunoTherapy of Cancer (JITC) in July 2021.
  • Recent studies have demonstrated that spatial biomarkers are able to predict immunotherapy response with greater accuracy than current methods1,2.
  • Among the parameters examined were tumor cell and immune cell subset densities, PD-L1 expression and location, and PD-1/PD-L1 spatial proximity.
  • All statements herein are based only on information currently available to us and speak only as of the date hereof.

Corvus Pharmaceuticals Discontinues Phase 3 Study of Mupadolimab (Anti-CD73) for COVID-19 Due to Vaccine Effectiveness in Reducing Hospitalizations

Retrieved on: 
Thursday, July 15, 2021

The Company will continue to advance the development of mupadolimab in oncology, where it is currently being studied in a Phase 1/1b clinical trial.

Key Points: 
  • The Company will continue to advance the development of mupadolimab in oncology, where it is currently being studied in a Phase 1/1b clinical trial.
  • Mupadolimab (formerly CPI-006) is a humanized anti-CD73 antibody that binds to various immune cells including most B cells.
  • Binding to CD73 inhibits production of immunosuppressive adenosine in the tumor microenvironment, similar to other recently described anti-CD73 antibodies.
  • In addition, Corvus has published results from the initial cohorts of its Phase 1 COVID-19 study and pre-clinical data characterizing the novel immunotherapy approach with mupadolimab online at medRxiv.org.